Business UpdateMay 13, 2026, 08:32 AM
Innate Pharma Q1 2026 Business Update; Cash €25.4M, Runway to Q3 2026
AI Summary
Innate Pharma provided its Q1 2026 business update, highlighting significant progress across its clinical pipeline. The confirmatory Phase 3 TELLOMAK-3 trial for lacutamab is planned for H2 2026, contingent on securing non-dilutive financing. The IPH4502 Nectin-4 ADC showed preliminary anti-tumor activity with a favorable safety profile, nearing completion of Phase 1 enrollment. Additionally, the PACIFIC-9 Phase 3 trial for monalizumab is on track for a H2 2026 data readout, and IPH5201 demonstrated encouraging interim results in the MATISSE Phase 2 study for NSCLC. The company reported a cash position of €25.4 million as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026.
Key Highlights
- Lacutamab TELLOMAK-3 Phase 3 trial planned for H2 2026, subject to non-dilutive financing.
- IPH4502 Phase 1 enrollment nearing completion, showing preliminary anti-tumor activity and favorable safety.
- PACIFIC-9 Phase 3 trial (monalizumab) data readout expected in H2 2026.
- IPH5201 MATISSE Phase 2 showed 27.5% overall pathological complete response rate in NSCLC.
- Cash position of €25.4 million as of March 31, 2026.
- Anticipated cash runway until the end of Q3 2026.
Price Impact
More from IPHA